Journal article

A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.

Nic Brereton, Keith Bodger, Michael A Kamm, Paul Hodgkins, Songkai Yan, Ron Akehurst

J Med Econ | Published : 2010

Abstract

OBJECTIVES: To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective. METHODS: A 5-year Markov cohort model was developed. Costs were obtained from the literature and utilities from an independent study. Uncertainty was evaluated using one-way and probabilistic sensitivity analyses (PSA). The potential effect of dosing frequency on adherence and possible long-term effects of remission maintenance on colorectal cancer (CRC) rates were also investigated. RESULTS: The model suggested that 5-year therapy with MMX mesalazine was likely to generate gain..

View full abstract